October 2011 Pritor®/Kinzal® HIGHCARE-Andes Study Initiated
Prof. Parati and colleagues investigate the ability of Pritor®/Kinzal® in combination with Adalat GITS® to combat blood pressure increases associated with high altitude
On the tail of the positive results of the TALENT trial, HIGHCARE-Andes (HIGH altitude CArdiovascular REsearch in the Andes) is a new study being undertaken by Professor Gianfranco Parati of the University of Milan-Biococca and colleagues to investigate the effectiveness of Pritor®/Kinzal® and Adalat GITS® on blood pressure at high altitude in hypertensive patients. Pritor®/Kinzal® is the first ARB to be tested in such conditions and the results will contribute to the strong evidence base established throughout the history of this unique compound.
more
Pritor®/Kinzal® - News & Views from Warsaw
It was Warsaw, Poland, known among other things for its world famous citizens Frédéric Chopin and Marie Skłodowska Curie, that welcomed on Saturday April 2nd the 7th edition of Bayer HealthCare Pritor®/Kinzal® (telmisartan) Stand Alone Symposium. Under the umbrella of the International Cardiovascular and Metabolic Academy (ICMA), close to 500 physicians, predominantly cardiologists and primary care physicians, joined this year’s meeting entitled “Novel Perspectives and Insights into Hypertension Treatment.”
more
Despite adverse weather conditions – there was a good attendance at the first HVD congress and Bayer symposium in Lisbon
The first 'Heart, Vessels & Diabetes European Conference' (Lisbon, Portugal, 9-11 December, 2010) gave Bayer Schering Pharma the opportunity to illustrate the commitment of the company in cardiovascular medicine. The Bayer-sponsored symposium 'Managing CV risk factors for disease prevention', which was held during the congress was also well-received, being attended by nearly 200 delegates.
more
August 2010, BSP Symposia at the ESC Congress, Stockholm, Sweden
Following the success and on-going findings from ONTARGET® (The ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) and TALENT® (A Multicentre STudy EvALuating the Efficacy of Nifedipine GITS – Telmisartan Combination in BP Control and Beyond: comparison of two strategies), BSP conducted 2 satellite symposia at the ESC Congress to present the trials' results and discuss their clinical implications.
more
June 2010 Pritor®/Kinzal® at the ESH 2010 in Oslo, Norway
Bayer Schering Pharma (BSP) presents initial findings from TALENT at the European Society of Hypertension (ESH) congress 2010
BSP’s successful programme of activities at ESH 2010 were focused on the rollout of the initial findings of TALENT (A Multicentre STudy EvALuating the Efficacy of Nifedipine GITS – Telmisartan Combination in BP Control and Beyond: comparison of two strategies). Kicking off events on Saturday 19th June was an exciting ‘Hotline’ presentation on TALENT by one of the principal investigators Professor Luis Ruilope (Spain) demonstrating that initiating antihypertensive treatment with the combination of Adalat® (nifedipine GastroIntestinal Therapeutic System) and Pritor®/Kinzal® (telmisartan) in patients at high cardiovascular risk allowed optimal blood pressure control to be achieved earlier compared with starting with add-on therapy.
more
Pritor®/Kinzalmono® receives new indication in broad spectrum CVD prevention
The European Commission has approved the label extension of Pritor®/Kinzalmono® (telmisartan). The new indication in cardiovascular prevention includes the reduction of cardiovascular morbidity in patients:
more
September, 2009: Pritor®/Kinzal® at the ESC 2009 in Barcelona, Spain
This year’s European Society of Cardiology (ESC) Congress, Aug 29 – Sep 2, Barcelona was yet again the world’s largest meeting in cardiovascular medicine, with over 30,000 attendees.
This renowned international meeting provided an opportunity for Bayer Schering Pharma (BSP) to showcase its impressive portfolio for the management of CVD and highlight the clinical benefits of Adalat® and Pritor®/Kinzal® in the management of hypertension and CVD.
Over the course of the congress, BSP sponsored an interactive product exhibition booth, where guest speakers gave mini-presentations and encouraged debates on ongoing questions around the optimal management of hypertension, which generated significant interest. BSP also sponsored a Satellite Symposium, “What more can we achieve beyond mono and combination therapy for hypertension management?” attended by nearly 400 delegates.
View the full satellite symposium online here.
more
June, 2009: Pritor®/Kinzal® at the 19th European Meeting on Hypertension, Milan
With a capacity seated and standing audience of nearly 500 delegates, this year's Bayer Schering Pharma (BSP) programme at 19th European Meeting on Hypertension, Milan, was a huge success. The Topical Workshop – Effective blood pressure lowering reduces cardiovascular risk – was part of the main congress programme and combined educational support for the use of both Pritor®/Kinzal® and Adalat. Chaired by Professors Athanasios Manolis (Greece) and Antonio Coca (Spain) the programme examined the need to manage difficult-to-treat hypertensive patients with appropriate, aggressive and early intervention. In addition, Prof. Paolo Verdecchia (Italy) presented preliminary data from the pre-specified LVH (left ventricular hypertrophy) analysis of the ONTARGET®-TRANSCEND® trials in the late breaking news session.
The official ESH webcast of the Bayer Schering Pharma educational session can be viewed online here.
more
4th Annual Pritor®/Kinzal® Stand Alone Symposium
(May, 2009) The 4th Annual Pritor®/Kinzal® Stand Alone Symposium entitled "Be On Target for More Life" recently took place in Lisbon, Portugal. Building on the 2008 Athens Standalone, leading experts presented the most recent evidence and opinions concerning the outcomes of the ONTARGET® Trial Programme & PRoFESS™ and their potential impact on clinical practice.
more
3rd Annual Pritor/Kinzal Stand Alone Symposium
(Oct, 2008) The 3rd Annual Pritor®/Kinzal® Stand Alone Symposium, recently took place in Athens, Greece, on 25 October 2008. Its purpose was to demonstrate and discuss the most recent evidence and clinical opinions concerning the successful outcomes of the ONTARGET® Trial Program. Cardiovascular disease is still the number one cause of death in first world countries and is predicted to become the leading cause of death in the developing world in the near future. Therefore, the prevention of health deterioration from cardiovascular events is a common treatment goal around the globe.
more
